MedPath

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

Registration Number
NCT01828697
Lead Sponsor
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Brief Summary

This is a randomized-controlled open-label trial comparing two different doses of low-molecular-weight heparin (LMWH) in pregnant patients with a history of previous venous thromboembolism (VTE). Both doses are recommended doses in the 2012 guidelines of the American College of Chest Physicians (ACCP), but it is not known which dose is more efficacious in preventing recurrent venous thromboembolism in pregnancy.

Patients enter the study and will be randomized as soon as a home test confirms pregnancy. LMWH will be administered until 6 weeks postpartum. Follow-up will continue until 3 months postpartum. Patients will be recruited by their treating physician, either an obstetrician or internist.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
1110
Inclusion Criteria
  • Age: 18 years or older, and;
  • Pregnancy confirmed by urinary pregnancy test, and;
  • Gestational age < 14 weeks, and;
  • Previous objectively confirmed VTE, either unprovoked, in the presence of use of oral contraceptives or estrogen/progestagen use, or related to pregnancy or the postpartum period, or minor risk factors (e.g. long distance travel, minor trauma).
Exclusion Criteria
  • Previous VTE related to a major provoking risk factor (e.g. surgery, major trauma or plaster cast immobilisation in the 3 months prior to VTE) as the sole risk factor, or;
  • Indication for treatment with therapeutic dose anticoagulant therapy (e.g. treatment of acute VTE; permanent use of therapeutic anticoagulants outside of pregnancy), or;
  • Inability to provide informed consent, or;
  • Any contraindication listed in the local labelling of LMWH.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Low dose LMWHFixed low dose tinzaparinFixed low dose low-molecular-weight heparin: * Fixed low dose nadroparin, or; * Fixed low dose enoxaparin, or; * Fixed low dose dalteparin, or; * Fixed low dose tinzaparin.
Low dose LMWHLow dose nadroparinFixed low dose low-molecular-weight heparin: * Fixed low dose nadroparin, or; * Fixed low dose enoxaparin, or; * Fixed low dose dalteparin, or; * Fixed low dose tinzaparin.
Low dose LMWHLow dose enoxaparinFixed low dose low-molecular-weight heparin: * Fixed low dose nadroparin, or; * Fixed low dose enoxaparin, or; * Fixed low dose dalteparin, or; * Fixed low dose tinzaparin.
Low dose LMWHLow dose dalteparinFixed low dose low-molecular-weight heparin: * Fixed low dose nadroparin, or; * Fixed low dose enoxaparin, or; * Fixed low dose dalteparin, or; * Fixed low dose tinzaparin.
Intermediate dose LMWHIntermediate dose nadroparinIntermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol. * Intermediate dose nadroparin, or; * Intermediate dose enoxaparin, or; * Intermediate dose dalteparin, or; * Intermediate dose tinzaparin.
Intermediate dose LMWHIntermediate dose enoxaparinIntermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol. * Intermediate dose nadroparin, or; * Intermediate dose enoxaparin, or; * Intermediate dose dalteparin, or; * Intermediate dose tinzaparin.
Intermediate dose LMWHIntermediate dose dalteparinIntermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol. * Intermediate dose nadroparin, or; * Intermediate dose enoxaparin, or; * Intermediate dose dalteparin, or; * Intermediate dose tinzaparin.
Intermediate dose LMWHIntermediate dose tinzaparinIntermediate dose low-molecular-weight heparin. Dosing is weight-adjusted according to the protocol. * Intermediate dose nadroparin, or; * Intermediate dose enoxaparin, or; * Intermediate dose dalteparin, or; * Intermediate dose tinzaparin.
Primary Outcome Measures
NameTimeMethod
Symptomatic confirmed deep venous thrombosisFrom date of randomization up to 6 weeks postpartum

All events of symptomatic deep venous thrombosis in subjects will be recorded from the the date of randomization up to 6 weeks postpartum.

Definition of symptomatic deep venous thrombosis (DVT):

Suspected (recurrent) DVT with one of the following findings:

If there were no previous DVT investigations:

* Abnormal compression ultrasound (CUS),

* An intraluminal filling defect on venography.

If there was a previous DVT investigation:

* Abnormal CUS where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression,

* An extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography.

Symptomatic confirmed pulmonary embolismFrom date of randomization up to 6 weeks postpartum

All events of symptomatic pulmonary embolism in subjects will be recorded from the the date of randomization up to 6 weeks postpartum.

Definition of symptomatic pulmonary embolism (PE):

Suspected PE with one of the following findings:

* A (new) intraluminal filling defect in subsegmental or more proximal branches on spiral CT scan

* A (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram

* A (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)

Secondary Outcome Measures
NameTimeMethod
Symptomatic confirmed deep venous thrombosisFrom date of randomization up to 3 months postpartum

All events of symptomatic deep venous thrombosis in subjects will be recorded from the the date of randomization up to 3 months postpartum.

Definition of symptomatic deep venous thrombosis (DVT):

Suspected (recurrent) DVT with one of the following findings:

If there were no previous DVT investigations:

* Abnormal compression ultrasound (CUS),

* An intraluminal filling defect on venography.

If there was a previous DVT investigation:

* Abnormal CUS where compression had been normal or, if non-compressible during screening, a substantial increase (4 mm or more) in diameter of the thrombus during full compression,

* An extension of an intraluminal filling defect, or a new intraluminal filling defect or an extension of non-visualization of veins in the presence of a sudden cut-off on venography.

Symptomatic confirmed pulmonary embolismFrom date of randomization up to 3 months postpartum

All events of symptomatic pulmonary embolism in subjects will be recorded from the the date of randomization up to 3 months postpartum.

Definition of symptomatic pulmonary embolism (PE):

Suspected PE with one of the following findings:

* A (new) intraluminal filling defect in subsegmental or more proximal branches on spiral CT scan

* A (new) intraluminal filling defect or an extension of an existing defect or a new sudden cut-off of vessels more than 2.5 mm in diameter on the pulmonary angiogram

* A (new) perfusion defect of at least 75% of a segment with a local normal ventilation result (high-probability) on ventilation/perfusion lung scan (VPLS)

Trial Locations

Locations (72)

CHU de Besancon

🇫🇷

Besançon, France

CHU de Brest

🇫🇷

Brest, France

Marseille St Joseph

🇫🇷

Marseille, France

CHU de Bordeaux

🇫🇷

Bordeaux, France

KU Leuven

🇧🇪

Leuven, Belgium

CHU de Nancy

🇫🇷

Nancy, France

CHU de Grenoble

🇫🇷

Grenoble, France

CHU de Limoges

🇫🇷

Limoges, France

Coombe Women's Hospital

🇮🇪

Dublin, Ireland

CHU de Caen

🇫🇷

Caen, France

Polyclinique de Sète

🇫🇷

Sète, France

University Hospital Limerick

🇮🇪

Limerick, Ireland

Spaarne Gasthuis

🇳🇱

Haarlem, Netherlands

MUMC

🇳🇱

Maastricht, Netherlands

St. Radboud UMC

🇳🇱

Nijmegen, Netherlands

Erasmus MC

🇳🇱

Rotterdam, Netherlands

Aarhus University Hospital

🇩🇰

Aarhus, Denmark

Letterkenny University Hospital

🇮🇪

Letterkenny, Ireland

Corke University Hospital

🇮🇪

Cork, Ireland

APHP Louis Mourier

🇫🇷

Colombes, France

Hopital Nord, CHU de Saint Etienne

🇫🇷

Saint Etienne, France

The Ottawa Hospital

🇨🇦

Ottawa, Canada

Weill Cornell Medicine | NewYork-Presbyterian

🇺🇸

New York, New York, United States

Aalborg University Hospital

🇩🇰

Aalborg, Denmark

CHU de Clermont - Ferrand

🇫🇷

Clermont-Ferrand, France

Hopiteaux de Marseille

🇫🇷

Marseille, France

CHU de Nice

🇫🇷

Nice, France

APHP Antoine Béclère

🇫🇷

Paris, France

CHU de Nîmes

🇫🇷

Nîmes, France

APHP Port Royal

🇫🇷

Paris, France

CHU de Poitiers

🇫🇷

Paris, France

Centra Hospitalier de Roanne

🇫🇷

Roanne, France

Flevoziekenhuis

🇳🇱

Almere, Netherlands

La Réunion - Saint-Denis

🇫🇷

Saint-Denis, France

CHIC de Toulon

🇫🇷

Toulon, France

Rotunda Hospital

🇮🇪

Dublin, Ireland

CHU de Tours

🇫🇷

Tours, France

La Réunion deSt Pierre

🇫🇷

Saint-Pierre, France

OLVG oost

🇳🇱

Amsterdam, Netherlands

The National Maternity Hospital

🇮🇪

Dublin, Ireland

Academic Medical Center

🇳🇱

Amsterdam, Noord-Holland, Netherlands

SLAZ

🇳🇱

Amsterdam, Netherlands

Jeroen Bosch Ziekenhuis

🇳🇱

's-Hertogenbosch, Netherlands

Gelre Ziekenhuizen

🇳🇱

Apeldoorn, Netherlands

VU medical center

🇳🇱

Amsterdam, Netherlands

Wilhelmina Ziekenhuis

🇳🇱

Assen, Netherlands

Amphia ziekenhuis

🇳🇱

Breda, Netherlands

Rijnstate hospital

🇳🇱

Arnhem, Netherlands

Rode Kruis Ziekenhuis

🇳🇱

Beverwijk, Netherlands

Reinier de Graaf Groep

🇳🇱

Delft, Netherlands

Bronovo ziekenhuis

🇳🇱

Den Haag, Netherlands

HAGA ziekenhuis

🇳🇱

Den Haag, Netherlands

Deventer Ziekenhuis

🇳🇱

Deventer, Netherlands

Slingeland

🇳🇱

Doetinchem, Netherlands

Albert Schweitzer

🇳🇱

Dordrecht, Netherlands

Gelderse Vallei

🇳🇱

Ede, Netherlands

Admiraal de Ruijter Ziekenhuis

🇳🇱

Goes, Netherlands

UMCG

🇳🇱

Groningen, Netherlands

Martini Ziekenhuis

🇳🇱

Groningen, Netherlands

Groene Hart Ziekenhuis

🇳🇱

Gouda, Netherlands

St Jansdal

🇳🇱

Harderwijk, Netherlands

Atrium MC

🇳🇱

Heerlen, Netherlands

MC Leeuwarden

🇳🇱

Leeuwarden, Netherlands

LUMC

🇳🇱

Leiden, Netherlands

Canisius-Wilhelmina Ziekenhuis

🇳🇱

Nijmegen, Netherlands

TweeSteden

🇳🇱

Tilburg, Netherlands

Diakonessen Utrecht

🇳🇱

Utrecht, Netherlands

UMCU

🇳🇱

Utrecht, Netherlands

Oslo University Hospital

🇳🇴

Oslo, Norway

Máxima MC

🇳🇱

Veldhoven, Netherlands

Vall d'Hebron Hospital

🇪🇸

Barcelona, Spain

Federal State Institution "Research Center for Obstetrics, Gynecology and Perinatology"

🇷🇺

Moscow, Russian Federation

© Copyright 2025. All Rights Reserved by MedPath